Today, the US FDA approved Erleada (apalutamide), an androgen receptor inhibitor created by Janssen Pharmaceuticals for the treatment of men with non-metastatic, castration-resistant prostate cancer. Erleada was approved after a priority review of...

"Researchers are hopeful about the potential for a novel agent in high-risk prostate cancer" states Tony Berberabe, MPh in his published article for Cure Magazine on June 23rd, 2016